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Abstract and Title Page
Abstract 
To explore the efficacy of cycle training in the treatment of intermittent claudication, the present study 
compared performance and physiological effects of cycle training with more conventional treadmill 
walking training in a group of claudicants. Forty two individuals with peripheral arterial disease and 
intermittent claudication (24 males, 18 females) were stratified on the basis of gender and the presence 
or absence of type 2 diabetes mellitus, and then randomized to a treadmill (n = 13), cycle (n = 15) or 
control group (n = 14). Treadmill and cycle groups trained three times a week for six weeks; whereas 
the control group did not train over this period. Maximal and pain-free exercise times were measured 
on graded treadmill and cycle tests before and after training. Treadmill training significantly improved 
maximal and pain-free treadmill walking times; but it did not improve cycle performance. Cycle 
training significantly improved maximal cycle time; but it did not improve treadmill performance. 
However, there was evidence of a stronger cross-transfer effect between the training modes for patients 
who reported a common limiting symptom during cycling and walking at baseline. There was also 
considerable variation in the training response to cycling, and a subgroup of ‘responsive’ patients in the 
cycle group improved their walking performance by more than the average response observed in the 
treadmill group. These findings suggest that cycle exercise is not effective in improving walking 
performance in all claudicants; but that it might be an effective alternative to walking in those 
claudicants who exhibit similar limiting symptoms during both types of exercise.  
 
Key words: intermittent claudication, training, cycle, treadmill, walking performance, O2 uptake, 
muscle pain 
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Introduction 
Improving exercise tolerance through supervised exercise training is an important part of the 
medical treatment of peripheral arterial disease (PAD) and intermittent claudication 1.  Walking 
has been the centerpiece of exercise training programs for several decades 2,3, and it is seen to be 
essential to maximizing the efficacy of training 4. However, adherence to walking can be difficult 
for many claudicants, as reflected in relatively high drop-out rates (~ 30 %) from walking 
programs 5, and so alternative modes of exercise might be useful for patients and treating 
clinicians alike.  The effectiveness of other modes of exercise such as cycling 6, resistance 
training 2,7, stairclimbing 8 and arm cranking 6 has been studied to a very limited extent. Of these 
alternative modes of exercise, cycling is attractive to study because it is a relatively easy, 
inexpensive and safe exercise to perform, as well as being a popular mode of transport in some 
countries. We have previously shown that the acute physiological responses to stationary cycling 
and treadmill walking are similar in patients with intermittent claudication 9. Although a recent 
study demonstrated some degree of benefit of cycling in the treatment of intermittent claudication 
6, the relative effectiveness of cycle training compared with the more conventional treadmill 
training is not known. Establishing this is important to the on-going process of improving the 
prescription of exercise for intermittent claudication. 
 
Therefore, the aim of this preliminary study was to compare the short-term effects of cycle 
training with treadmill training on exercise tolerance and physiological responses to exercise in 
claudicants. Performance and physiological responses to both treadmill and cycle exercise were 
assessed so that the cross-transfer of effects between exercise modes could also be determined.  
 
* Redline Manuscript
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Methods 
Subject Identification          Six-hundred-and-ninety-four (694) patients with a reduced ABI 
(<0.9) in at least one limb and a documented history (>1 year) of intermittent claudication were 
consecutively identified over a 17-month recruitment period.  The majority of excluded patients 
either lived further than 50 km from the research venue (n=340), did not respond to the invitation 
to participate (n=88), or were unable to participate for personal reasons (n=87).  Other patients 
deemed ineligible included those with reduced cardiac function or unstable angina (n=60), rest 
pain (n=18), recently undergoing surgery or suffering a cardiovascular event (n=20), or other 
medical conditions for which exercise testing and training were contraindicated (n=9).   
 
Subject Screening and Randomization             Seventy-two (72) patients were identified for 
further screening and gave their written informed consent to the experimental procedures, which 
were approved by the ethics committees of the Royal Brisbane and Women's Hospital, University 
of Queensland and Queensland University of Technology.  The pre-study screening test was a 
maximal graded treadmill test with ECG monitoring and pre- and post-exercise ABI 
measurements. Five (5) patients were subsequently excluded as they were not primarily limited 
by claudication, and a further 19 patients were excluded because of ischemic ECG changes or 
uncontrolled hypertension.  The remaining 43 patients were limited by claudication, displayed a 
positive ABI response during walking (20 mmHg fall), and were therefore eligible for 
randomization. 
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Subjects were stratified on the basis of gender and the presence or absence of diabetes to ensure 
an equal distribution of these characteristics among the experimental groups. That is, prior to 
randomization, subjects were allocated to the following groups: male diabetic, male non-diabetic, 
female diabetic, or female non-diabetic.  From these stratified groups, subjects were then 
randomized to a control group, a cycle-training group or a treadmill-training group using a closed 
envelope system.  One subject randomized to the treadmill-training group withdrew from the 
study after one week of training due to work-related commitments and their baseline data has 
been omitted. Body weight and heart rate were measured during quiet rest prior to baseline 
treadmill testing and across the training period. Baseline characteristics of the 42 claudicants are 
shown in Table 1. 
 
Sample Size and Statistical Power  Maximal walking performance was the variable about 
which estimates of the current sample sizes (n ≥ 13 per group) and statistical power (> 0.8) were 
made. In designing this study we were most concerned with detecting changes in walking 
performance in response to treadmill training (compared with control) and cycle training (compared 
with control).  Coefficients of variation for walking performance (c.v. = 13-17%), as well as the mean 
pre-training values, were used to determine the SD for repeated measurements on each variable.  The 
minimum “meaningful change” or difference in the variable is equal to two SDs, a very conservative 
value that served as the difference score used to compute the corresponding effect sizes.  All SDs of 
difference scores were imputed from averaged SDs of the pre-and post-training scores found in 
another study (20) that used similar measurement techniques to those adopted in the present study.   
 
Control Group Claudicants in the control group were managed with standard 
cardiovascular  risk factor modification – that is, the appropriate antiplatelet therapy and 
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pharmacotherapy for hypertension, diabetes and hypercholesterolaemia, as well as advice 
concerning the need to stop smoking and to exercise.  
 
Training Groups Claudicants in the treadmill and cycle training groups were also managed 
with standard cardiovascular risk factor modification, and in addition they performed three 
supervised training sessions per week for a period of six weeks. Prior to and following each 
exercise session patients completed a series of lower limb stretching exercises. During each 
training session subjects completed ten, two minute bouts of exercise with each bout separated by 
two minutes of rest. Walking was performed on motorized treadmills (Cybex Trotter 700T, 
Medway MA, U.S.A) and cycling was performed on cycle ergometers (Monark 818 Ergomedic, 
Vansbro, Sweden). The training intensity corresponded to a workload that elicited an O2 uptake 
(VO2) equal to 80% of the peak value measured during the baseline incremental walking or 
cycling tests (see below). This workload was maintained during the first three weeks of the 
supervised program, and then during the last three weeks of training the intensity was increased 
to the maximum workload achieved during the baseline test.  Heart rate (Polar Electro-Oy 
Fitwatch, Kempele, Finland) and patient-reported claudication pain severity  (0 = no pain; 1 = 
mild pain; 2 = moderate pain; 3 = maximal pain) were recorded during each exercise bout.   
 
Exercise Testing Prior to training, all subjects performed an initial screening treadmill test to 
maximum claudication and then a separate session aimed at familiarizing them with all the 
testing apparatus and exercise protocols. Subjects then completed at least two maximal graded 
treadmill walking tests and two maximal graded cycle tests over a 2-week period on four separate 
days. A third test was conducted if there was more than a 25 % difference in maximum walking 
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or cycling times between the two tests 10. Performance on the last tests was taken to represent a 
pre-training score. 
 
The maximal graded walking test was performed on a motorized treadmill (TrackMaster 
TMX425CP, Newton, KS, U.S.A.) at a constant speed of 2.7 km h-1. The treadmill gradient was 
initially set at 0 % for the first five minutes of the test, and then it was increased by 2 % every 
three minutes until the patient failed to sustain the task. Pain-free walking time (PFWT) and the 
total time spent walking (MWT) were recorded.  This protocol is similar to that used previously 
by our group 9,11-14 and it is highly reproducible (average CV = 6 %) when conducted after the 
above-mentioned familiarization routine 12. The maximal graded cycle test was performed on an 
electrically-braked cycle ergometer (Lode Rehcor; Groningen, Netherlands) at a cadence of 60 
rpm. For the first five minutes of the test the power output was set at 30 W, and thereafter it was 
increased 10 W each three minutes until the subject failed to sustain the required cadence. Pain-
free cycling time (PFCT) and the total time spent cycling (MCT) were recorded. During the 
treadmill and cycle tests, the site(s) and severity of claudication pain were assessed every 60 s 
and at the end of exercise using the above-mentioned scale. 
 
Physiological Measurements  Heart rate and pulmonary gas exchange data were collected 
for two minutes prior to exercise, while the subject was seated on the cycle ergometer or standing 
on the treadmill, as well as throughout exercise.  Heart rate (HR) was measured with a portable 
heart rate monitor (Polar Electro-Oy S610i, Kemple, Finland) and averaged over 5 second 
intervals.  Minute ventilation (VE), rates of oxygen consumption (VO2) and carbon dioxide 
production (VCO2), and the respiratory exchange ratio (RER = VCO2/VO2) were measured breath-
by-breath and averaged over 5 second intervals (MedGraphics CPX/D, St. Paul, MN, USA).  
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Submaximal gas exchange and HR values were calculated by averaging all 5 second samples 
recorded between the 3 min 50 s and 4 min 45 s period of the first five minute exercise stage. To 
identify peak values, HR and gas exchange variables were averaged over 15 second intervals and 
the highest values recorded during the last three minutes of the exercise test were taken as the 
peak values.  
 
The ankle:brachial index (ABI) was measured in triplicate at rest, after 20 minutes of lying 
quietly, in both legs.   The ABI was calculated using the systolic pressures of the highest brachial 
artery and the higher of the dorsalis pedis or posterior tibial arteries, all of which were measured 
within 60 s of each other.  An average resting ABI value for each leg was obtained by averaging 
the closest two of the triplicate measures.  Immediately after each exercise test, subjects returned 
to a supine position and single measures of the ABI of both legs were repeated at 2, 4, 6, 8 and 10 
minutes after exercise.  The same ankle and brachial arteries used to calculate the resting ABI 
were measured during the post-exercise period.  Ankle pressures were measured with an 
inflatable cuff and Doppler ultrasound (8MHz) probe (Huntleigh Muti-Doplex, Cardiff, UK), 
while brachial pressures were measured with an automated pressure monitor (Criticon Dinamap, 
Florida, U.S.A).   
 
Data Analysis  Only values of variables measured during the last of the baseline tests and 
the post-training test were included in the analyses described below. Difference or “change” 
scores were calculated as the difference between the last of the baseline test and post-training test 
scores. All variables were tested for normality using the Kolmogorov-Smirnov test, and in cases 
where variables were not normally distributed a log transformation was applied to stabilise the 
variance. A three-way repeated measures ANOVA (group; time; limb) was used to detect main 
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effects and interactions for the resting and post-exercise (minimum value) ABI data. A two-way 
repeated measures ANOVA was used to detect main effects (group; time) and interactions (group 
× time) for all other variables. The “time” factor represents the six week period of training. 
Tukey’s HD test was used to locate differences when an ANOVA result was significant. 
Relationships between variables were established using Pearson’s correlation coefficient. All data 
are expressed as means and SDs, unless otherwise stated. Statistical significance was set at p < 
0.05. 
 
 
 
 
Results 
Baseline characteristics of the 42 claudicants are shown in Table 1. Patients were well matched 
for age, gender and cardiovascular risk factors. Smoking behaviour and exercise behaviour 
beyond the supervised training were assessed using validated questions from the National Health 
Survey of Australia, and these behaviours remained unchanged in all subjects over the training 
period. The lack of change in exercise behaviour was also confirmed by the results of physical 
activity surveys that were conducted before and after training.  There were no significant main 
effects (group or time) or interaction for resting and post-exercise (treadmill and cycle) ABI 
responses, body weight and resting heart rate, suggesting these responses were similar before and 
after training.  
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Training Sessions Subjects in the treadmill group completed a similar number of training 
sessions (16.6 ± 1.0) as those in the cycle group (17.0 ± 2.3), and the total dose of training was 
not different (p = 0.37) between the treadmill (22.04 ± 7.64 MET hours) and cycle (22.64 ± 7.46 
MET hours) groups. The heart rate at the end of each exercise bout, averaged over all training 
sessions, was not significantly different (p = 0.14; student’s t-test) between the cycle (114 ± 24 
bpm) and treadmill (101 ± 19 bpm) groups.  Mean claudication pain severity during cycle 
training was 1.2 ± 0.7 in the high ABI leg and 1.6 ± 0.5 in the low ABI leg. These values were 
significantly higher (p < 0.05) than the corresponding values observed in the treadmill training 
group (0.5 ± 0.5 and 1.0 ± 0.7 respectively).  
 
Treadmill Test  Prior to training, neither MWT nor PFWT were different between the 
groups. As shown in Figure 1, MWT was significantly increased by training in the treadmill 
group (mean difference = 240 s; 95% CI = 119-361 s); whereas there was no significant change 
in the cycle (mean difference = 48 s; 95% CI = -22 – 117 s) or control group (mean difference = -
10 s; 95 % CI = -90 – 71 s). This change in MWT in the treadmill group was significantly greater 
than the corresponding change scores in the cycle and control groups. This outcome was not 
affected by the exclusion of two claudicants who reported  only mild or moderate claudication 
during the baseline treadmill test. As shown in Figure 2, following training PFWT was 
significantly longer (p < 0.05) for the treadmill group (412 ± 251 s to 607 ± 369 s) compared with 
the cycle group (271 ± 289 s to 263 ± 293 s) and control group  (391 ± 411 s to 446 ± 442 s).  
Submaximal and peak responses for heart rate and pulmonary gas exchange measurements during 
the treadmill test are shown in Tables 2 and 3. In the treadmill group, the change in MWT was 
significantly correlated (p < 0.05) with the training-induced changes in submaximal heart rate (r 
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= - 0.55; 95 % CI = -0.73 - -0.30), peak VO2 (l min-1; r = 0.77; 95 % CI = 0.61 – 0.87) and peak 
heart rate (r = 0.54; 95 % CI = 0.28 – 0.72). 
 
Cycle Test  Prior to training, MCT was not significantly different between the groups. 
As shown in Figure 3, MCT was significantly increased by training in the cycle group (mean 
difference = 93 s; 95 % CI = 45 - 132 s); whereas it was not significantly increased in the 
treadmill (mean difference = 45 s; 95 % CI = -60 – 149 s) or control group (mean difference = 51 
s; 95 % CI = -128 – 230 s) (Figure 3). This change in MCT in the cycle group was significantly 
greater than the corresponding change score in the control group; but it was not significantly 
greater than the change score in the treadmill group. PFCT was also not different between the 
groups prior to training, and it was not affected by training (Figure 4). Submaximal and peak 
responses for heart rate and pulmonary gas exchange measurements during the cycle test are 
shown in Tables 2 and 3. In the cycle group, the change in MCT was not correlated with any 
other measured variable. 
 
Cycle versus Walking Tests  For the entire cohort, pain-free times on the baseline cycle 
and treadmill tests were not significantly different from each other; whereas MWT was 
significantly larger than MCT (difference = 179 ± 410 s; 95 % CI = 51.7 to 307.5 s; paired t-test). 
Submaximal and peak physiological responses were not different between these cycle and 
treadmill tests. Many of these responses to both baseline exercise tests (i.e. cycle vs treadmill) 
were significantly correlated (p < 0.05), particularly maximal exercise time (r = 0.75), peak VO2 
(r = 0.91) and ABI two minutes after exercise in the low ABI (r = 0.83) and high ABI leg (r = 
0.86).  The number of symptoms that limited performance and were cited as the reasons for 
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stopping exercise varied between one and three and there was some variation in the anatomical 
location of these symptoms. For the baseline treadmill test these symptoms included pain in the 
calves (n = 33), gluteals (n = 8), hamstrings (n = 7) and quadriceps (n = 4), as well as dyspnoea 
(n = 5) and ‘general fatigue’ (n = 5). Six subjects did not cite claudication as a main reason for 
stopping treadmill exercise, although four of them reported maximal claudication pain during the 
test. Two of these subjects reported only mild or moderate pain during baseline treadmill testing, 
despite the fact that they reported maximal claudication during the screening treadmill test prior 
to baseline testing. For the baseline cycle test the limiting symptoms included pain in the 
quadriceps (n = 27), calves (n = 16), hamstrings (n = 2) and gluteals (n = 1), as well as dyspnoea 
(n = 8) and general fatigue (n = 4).  Five subjects did not cite claudication as a main reason for 
stopping cycle exercise, and two of them did not experience claudication during the test. Half of 
the subjects (n = 21) shared at least one similar limiting symptom between the baseline cycle and 
treadmill tests.   
 
Treadmill training had a significantly larger effect (p < 0.05) on MWT (240 ± 178 s) than cycle 
training had on MCT (93 ± 98 s). Training pain level in the low ABI limb tended to be correlated 
(p = 0.06) with the effect of treadmill training on MWT (r = - 0.54; n = 13; 95 % CI = -0.84 -
0.02); but it was not correlated (r = - 0.2) with the effect of cycle training on MCT. In all trained 
subjects, training pain level in the low ABI limb was inversely correlated to the specific effect of 
training on maximal exercise time (r = -0.53; n = 28; 95 % CI = -0.75 - -0.20). With respect to the 
effects of training on cycle and treadmill performance in all trained subjects (n = 28), there were 
no significant correlations between the changes in maximal cycling and treadmill times (r = 0.01 
- 0.27). However, there was a significant correlation between the training-induced changes in 
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maximal cycle and treadmill times in those subjects who reported at least one limiting symptom 
that was in the same anatomical location during treadmill and cycle exercise before training (Fig. 
5A); but there was no correlation in those who reported limiting symptoms in a different 
anatomical location during treadmill and cycle exercise (Fig. 5B).  Age was also significantly 
correlated with the effect of cycle training on MWT (r = 0.62; p < 0.05). 
 
Responders versus Non-responders  For each subject who trained, a positive response to 
training occurred if the effect of training on maximal exercise time exceeded the difference 
between the last two baseline tests (i.e. MWT for treadmill group; MCT for cycle group). 
According to this criterion, 11 out of the 13 subjects in the treadmill group and 8 out of the 15 
subjects in the cycle group responded positively to training. A similar analysis in the control 
group (i.e. post-pre scores versus baseline variation) revealed three responders for MWT and one 
responder for MCT. Comparisons of baseline characteristics, baseline performances and training 
variables between responders (n = 19) and non-responders (n = 9) were performed. Only training 
pain severity in the low ABI leg was significantly different (p < 0.05) between the responders 
(1.1 ± 0.7) and non-responders (1.8 ± 0.6). 
   
Discussion 
Optimising the exercise program for claudicants depends on knowing the effects of the various 
dimensions of training, such as intensity, duration and mode. A metaanalysis of training studies 
performed up until the mid-1990s suggested that an optimal exercise program aimed at 
improving walking performance should use walking as the mode of exercise 4. This suggestion, 
however, was based on studies that did not systematically compare the effects of alternative 
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modes of exercise with walking. The present study is the first to contrast cycle with treadmill 
training, controlling for all other major dimensions of training, and it is one of only eight 
randomized controlled exercise trials to have studied more than 40 patients. Six weeks of 
treadmill training improved graded walking performance by, on average, 25 %. In contrast, cycle 
training did not improve graded walking performance, despite the finding that it significantly 
improved graded cycle performance. In addition, although treadmill training improved walking 
performance, it failed to increase cycle performance. These preliminary findings suggest that the 
training effects induced by cycling or walking are specific to the mode of exercise used during 
training and that there is no “cross-training” benefit.  
  
In the treatment of walking intolerance, the efficacy of alternative modes of exercise requires that 
there is a significant transfer of physiological adaptation to walking. The findings of our study 
suggest that this is generally not the case for cycling, despite the strong associations between 
cycling and walking performance before and after training (r = 0.72 - 0.75). Claudication in the 
calf and quadriceps muscles were the most frequently cited symptoms during treadmill walking 
and cycling respectively. It is perhaps this difference in the location of claudication between the 
two modes of exercise that has lead some to suggest that cycling would not be beneficial to PAD 
patients who most frequently claudicate in the calf 15. However, the number of limiting symptoms 
during both modes of exercise varied between one and three (see Results), and 50 % of the 
subjects reported a similar limiting symptom during cycling and treadmill exercise. Among the 
two groups of claudicants that trained (n = 28) and who had a similar limiting symptom between 
cycling and walking (n = 12), evidence of a cross-training effect was observed in the form of a 
significant association between the training effects on maximum walking and cycle times (Figure 
5). Seven of these claudicants were in the cycle group, and five of them improved their maximum 
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walking time (mean increase = 35 %) beyond the baseline variation in this measurement and by 
more than the mean response seen in the treadmill group. These data suggest that the similarity of 
symptoms between cycling and walking might help determine the effect of cycle training on 
walking performance. However, age was also positively related to the effect of cycle training on 
maximum walking time, and so we cannot exclude the possibility that age affects the 
responsiveness to training. Further research is clearly required to explore if the similarity of 
symptoms between exercise modes and/or age influences the performance benefit obtained from 
cycle training.  
 
A novel finding of the present study was the larger effect of treadmill training on maximal 
walking time compared with the effect of cycle training on maximal cycle time. This larger, 
specific effect of treadmill training (mean increase = 24 vs 10 %) could not be attributed to 
differences in any of the measured baseline characteristics (Table 1) or other dimensions of 
training, which were similar between the training programs. Excluding nonresponders from 
analyses had little effect on this difference in training effect. In contrast, levels of training pain in 
both limbs were significantly higher in the cycle than the treadmill group, and training pain level 
in the low ABI limb was inversely related to the specific effect of training on maximal exercise 
time.  These data raise the possibility that the smaller training response to cycling might be 
related to the significantly higher pain levels reported by the cycle group. Moreover, they suggest 
that in response to both forms of training a greater improvement in exercise tolerance occurred in 
those subjects who experienced lower and mild levels of claudication pain during the training 
sessions. This conflicts with the suggestion that an optimal training program for claudicants 
consists of exercise to near-maximal pain 4. Further study of this link between training pain and 
 14
physiological adaptation to training is required because the present data suggest that high levels 
of claudication pain might not be optimal. 
 
Although a number of studies have examined the training effects of cycling combined with other 
forms of exercise, only one other study has tested the effects of cycle training alone 6. That study 
reported that walking performance was improved significantly by cycle training. In trying to 
explain how this effect differs from that observed in the present study, several factors need to be 
considered. First, it is unlikely that the training stimulus was relatively lower in the present study 
because the training program was modeled on that used by Walker et al. 6 and training was 
performed more frequently (3 vs 2 sessions per week). Moreover, the increase in cycle 
performance and peak VO2 demonstrates that it provided a significant physiological stimulus. 
Second, our familiarization routine of several baseline testing sessions 9,11-14,16 might help reduce 
the confounding influence that task learning and lowered anxiety makes to the so-called training 
responses, and it is not clear what familiarisation was provided in the other study 6. Third, in 
contrast to the treadmill testing of one patient at a time, these investigators used an indoor shuttle 
walk test where ‘more than one patient’ was tested simultaneously. All but one of the 24 subjects 
in their cycle training group appeared to improve their maximum walking distance, and this 
relatively homogenous response raises the question as to the psychological influence of training 
and performing tests together on an individual’s walking performance after training. Fourth, one 
subject in their study appeared to improve their performance by more than 1000 %, and while this 
wouldn’t affect the significance of the group effect it would greatly inflate the average size of the 
effect reported (i.e. 50 %).  Fifth, the symptoms that limited walking performance were not 
reported in this study, and the heart rates measured during exercise (~160 bpm) far exceed the 
maximal heart rates of 110-120 bpm observed in the present and other studies 2,9,20. This raises 
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the possibility that cardiac dysfunction and symptoms other than claudication contributed more to 
exercise limitations than was the case in the present study.  
 
Over several decades there has been considerable interest in the physiological mechanisms that 
underpin the training effect on exercise tolerance in PAD 3,17,18; yet despite this and the large 
number of factors suggested to be involved in the training response this problem is not well 
understood 19. An improvement in performance might be underpinned by an improvement in 
exercise time in the absence and/or presence of pain, as well as the physiological responses 
associated with these two phases of exercise. In the present study, pain-free time during the 
treadmill test was improved significantly by treadmill training, and this improvement explained 
more than 80 % of the increase in maximal time on this test. In contrast, cycle training had no 
significant effect on pain-free time during the cycle test and, thus, made very little contribution to 
the increase in maximal cycle time. Thus, the specific effect of training differs markedly between 
cycling and walking: the improvement in maximal performance induced by both modes of 
training is linked mainly to a delay in the onset of pain for walking, and an extension of the time 
spent exercising with pain for cycling. This novel finding raises the possibility that the 
physiological adaptations to training also differ between cycling and walking.  
 
In the present study, we used a graded exercise protocol with an initial stage of 5 min duration 
that enables physiological responses to reach a steady-state in most patients 12,13,16. For treadmill 
exercise, there was a tendency towards a significant interactive effect on submaximal VO2 
(group-by-test: p = 0.07), where VO2 was lowered by training in the treadmill, but not cycle, 
group. These data are consistent with the above-mentioned effects of treadmill training on pain-
free time during treadmill walking, demonstrating a link between increased time without pain and 
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a lowered O2 cost of exercise during this mode of exercise.  These findings are similar to those 
observed after the same 6,20 or longer periods of training 2,5,20, where VO2 and blood lactate 
concentration during treadmill exercise were reduced by treadmill training.  However, neither of 
these studies nor the present study shed light on how the oxygen cost of exercise was lowered; 
but it might relate to improved walking technique, recruitment of a smaller number of motor units 
and/or recruitment of less economical type II muscle fibres 11. In contrast to the submaximal VO2 
response, peak VO2 was not significantly increased during treadmill exercise by treadmill 
training, a finding consistent with the only other training study of the same duration to have made 
these measurements 20. However, peak VO2 during cycle exercise was significantly increased by 
cycle training.  This suggests that the improvement in cycle performance in the cycle group, 
which was underpinned by an increase in the time spent exercising with pain, was linked to 
increases in the peak rates of O2 delivery to, and/or O2 consumption by, working muscles. 
 
Some limitations of this study should be considered. Although the sample size of this study 
compares favourably with other randomized controlled exercise training studies, small effects 
might go undetected and a type II error might have occurred. This probably applies most to the 
effect of cycle training given that it increased walking performance by an average of ~5 % more 
than the effect observed in the control group. Whether or not such an effect on a graded test 
translates into a clinically relevant effect in the life of a patient is difficult to determine at present. 
The study was powered to detect larger differences (~10 %) in graded treadmill performance than 
were observed for the control group; but given the natural variation in exercise performance as 
measured in our hands (CV~5-10 %), improvements less than this are of questionable 
significance, from a physiological and clinical perspective. Given the number of comparisons 
made in this study and the fact the we did not adjust the level of significance accordingly, we 
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acknowledge that we might have committed a type I error for any of the significant effects or 
correlations we observed . The duration of the study was restricted to 6 weeks, and given that 
longer training programs will elicit larger increases in performance, it is possible that the present 
study underestimates the training benefit that might be obtained with cycling. However, the 
duration of the training program studied here is consistent with the trend in some countries, such 
as Australia and the U.S., of providing relatively short periods of supervised intervention that are 
then followed by longer periods of home-based intervention and allied health support.  
 
In conclusion, this is the first study to compare the effect on walking performance induced by 
cycle or treadmill training in PAD patients with claudication. On average, cycle training over a 
six week period did not significantly improve walking performance. There was, however, 
considerable variation in the response to cycle training, with five out of the 15 claudicants in the 
cycle group improving their walking performance. This responsiveness to training might be 
influenced by age, the severity of muscle pain during training and/or the similarity of symptoms 
between cycling and walking. These preliminary findings deserve further study before cycle 
training is abandoned as a potential exercise prescription for selected patients with claudication.   
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Figure Captions 
 
Figure 1. Maximum walking times before and after training for patients in the treadmill, cycle 
and control groups. Figure shows individual walking times (—) and mean values (●). * Indicates 
a significant change in MWT from pre-training to post-training in the treadmill group.        
Figure 2. Pain-free walking times before and after training for patients in the treadmill, cycle and 
control groups. Figure shows individual walking times (—) and mean values (●).† a significant 
main effect where the treadmill group was greater than the cycle group. ‡ a significant main 
effect where post-training values were greater than pre-training values.    
Figure 3. Maximum cycling times before and after training for patients in the treadmill, cycle and 
control groups. Figure shows individual walking times (—) and mean values (●).* a significant 
effect of training on MCT in the cycle group.  
 
Figure 4. Pain-free cycling time before and after training for patients in the treadmill, cycle and 
control groups. Figure shows individual walking times (—) and mean values (●).  
Figure 5. The relationship between the training-induced changes in maximal treadmill and cycle 
times in claudicants who reported at least one exercise-limiting symptom that was in the same 
anatomical location (A) or exercise-limiting symptoms that were in a different anatomical 
location (B) during baseline treadmill and cycle tests.  
 
 
 
 1
Introduction 
Improving exercise tolerance through supervised exercise training is an important part of the 
medical treatment of peripheral arterial disease (PAD) and intermittent claudication 1.  Walking 
has been the centerpiece of exercise training programs for several decades 2,3, and it is seen to be 
essential to maximizing the efficacy of training 4. However, adherence to walking can be difficult 
for many claudicants, as reflected in relatively high drop-out rates (~ 30 %) from walking 
programs 5, and so alternative modes of exercise might be useful for patients and treating 
clinicians alike.  The effectiveness of other modes of exercise such as cycling 6, resistance 
training 2,7, stairclimbing 8 and arm cranking 6 has been studied to a very limited extent. Of these 
alternative modes of exercise, cycling is attractive to study because it is a relatively easy, 
inexpensive and safe exercise to perform, as well as being a popular mode of transport in some 
countries. We have previously shown that the acute physiological responses to stationary cycling 
and treadmill walking are similar in patients with intermittent claudication 9. Although a recent 
study demonstrated some degree of benefit of cycling in the treatment of intermittent claudication 
6, the relative effectiveness of cycle training compared with the more conventional treadmill 
training is not known. Establishing this is important to the on-going process of improving the 
prescription of exercise for intermittent claudication. 
 
Therefore, the aim of this preliminary study was to compare the short-term effects of cycle 
training with treadmill training on exercise tolerance and physiological responses to exercise in 
claudicants. Performance and physiological responses to both treadmill and cycle exercise were 
assessed so that the cross-transfer of effects between exercise modes could also be determined.  
 
* Manuscript
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Methods 
Subject Identification          Six-hundred-and-ninety-four (694) patients with a reduced ABI 
(<0.9) in at least one limb and a documented history (>1 year) of intermittent claudication were 
consecutively identified over a 17-month recruitment period.  The majority of excluded patients 
either lived further than 50 km from the research venue (n=340), did not respond to the invitation 
to participate (n=88), or were unable to participate for personal reasons (n=87).  Other patients 
deemed ineligible included those with reduced cardiac function or unstable angina (n=60), rest 
pain (n=18), recently undergoing surgery or suffering a cardiovascular event (n=20), or other 
medical conditions for which exercise testing and training were contraindicated (n=9).   
 
Subject Screening and Randomization             Seventy-two (72) patients were identified for 
further screening and gave their written informed consent to the experimental procedures, which 
were approved by the ethics committees of the Royal Brisbane and Women's Hospital, University 
of Queensland and Queensland University of Technology.  The pre-study screening test was a 
maximal graded treadmill test with ECG monitoring and pre- and post-exercise ABI 
measurements. Five (5) patients were subsequently excluded as they were not primarily limited 
by claudication, and a further 19 patients were excluded because of ischemic ECG changes or 
uncontrolled hypertension.  The remaining 43 patients were limited by claudication, displayed a 
positive ABI response during walking (20 mmHg fall), and were therefore eligible for 
randomization. 
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Subjects were stratified on the basis of gender and the presence or absence of diabetes to ensure 
an equal distribution of these characteristics among the experimental groups. That is, prior to 
randomization, subjects were allocated to the following groups: male diabetic, male non-diabetic, 
female diabetic, or female non-diabetic.  From these stratified groups, subjects were then 
randomized to a control group, a cycle-training group or a treadmill-training group using a closed 
envelope system.  One subject randomized to the treadmill-training group withdrew from the 
study after one week of training due to work-related commitments and their baseline data has 
been omitted. Body weight and heart rate were measured during quiet rest prior to baseline 
treadmill testing and across the training period. Baseline characteristics of the 42 claudicants are 
shown in Table 1. 
 
Sample Size and Statistical Power  Maximal walking performance was the variable about 
which estimates of the current sample sizes (n ≥ 13 per group) and statistical power (> 0.8) were 
made. In designing this study we were most concerned with detecting changes in walking 
performance in response to treadmill training (compared with control) and cycle training (compared 
with control).  Coefficients of variation for walking performance (c.v. = 13-17%), as well as the mean 
pre-training values, were used to determine the SD for repeated measurements on each variable.  The 
minimum “meaningful change” or difference in the variable is equal to two SDs, a very conservative 
value that served as the difference score used to compute the corresponding effect sizes.  All SDs of 
difference scores were imputed from averaged SDs of the pre-and post-training scores found in 
another study (20) that used similar measurement techniques to those adopted in the present study.   
 
Control Group Claudicants in the control group were managed with standard 
cardiovascular  risk factor modification – that is, the appropriate antiplatelet therapy and 
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pharmacotherapy for hypertension, diabetes and hypercholesterolaemia, as well as advice 
concerning the need to stop smoking and to exercise.  
 
Training Groups Claudicants in the treadmill and cycle training groups were also managed 
with standard cardiovascular risk factor modification, and in addition they performed three 
supervised training sessions per week for a period of six weeks. Prior to and following each 
exercise session patients completed a series of lower limb stretching exercises. During each 
training session subjects completed ten, two minute bouts of exercise with each bout separated by 
two minutes of rest. Walking was performed on motorized treadmills (Cybex Trotter 700T, 
Medway MA, U.S.A) and cycling was performed on cycle ergometers (Monark 818 Ergomedic, 
Vansbro, Sweden). The training intensity corresponded to a workload that elicited an O2 uptake 
(VO2) equal to 80% of the peak value measured during the baseline incremental walking or 
cycling tests (see below). This workload was maintained during the first three weeks of the 
supervised program, and then during the last three weeks of training the intensity was increased 
to the maximum workload achieved during the baseline test.  Heart rate (Polar Electro-Oy 
Fitwatch, Kempele, Finland) and patient-reported claudication pain severity  (0 = no pain; 1 = 
mild pain; 2 = moderate pain; 3 = maximal pain) were recorded during each exercise bout.   
 
Exercise Testing Prior to training, all subjects performed an initial screening treadmill test to 
maximum claudication and then a separate session aimed at familiarizing them with all the 
testing apparatus and exercise protocols. Subjects then completed at least two maximal graded 
treadmill walking tests and two maximal graded cycle tests over a 2-week period on four separate 
days. A third test was conducted if there was more than a 25 % difference in maximum walking 
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or cycling times between the two tests 10. Performance on the last tests was taken to represent a 
pre-training score. 
 
The maximal graded walking test was performed on a motorized treadmill (TrackMaster 
TMX425CP, Newton, KS, U.S.A.) at a constant speed of 2.7 km h-1. The treadmill gradient was 
initially set at 0 % for the first five minutes of the test, and then it was increased by 2 % every 
three minutes until the patient failed to sustain the task. Pain-free walking time (PFWT) and the 
total time spent walking (MWT) were recorded.  This protocol is similar to that used previously 
by our group 9,11-14 and it is highly reproducible (average CV = 6 %) when conducted after the 
above-mentioned familiarization routine 12. The maximal graded cycle test was performed on an 
electrically-braked cycle ergometer (Lode Rehcor; Groningen, Netherlands) at a cadence of 60 
rpm. For the first five minutes of the test the power output was set at 30 W, and thereafter it was 
increased 10 W each three minutes until the subject failed to sustain the required cadence. Pain-
free cycling time (PFCT) and the total time spent cycling (MCT) were recorded. During the 
treadmill and cycle tests, the site(s) and severity of claudication pain were assessed every 60 s 
and at the end of exercise using the above-mentioned scale. 
 
Physiological Measurements  Heart rate and pulmonary gas exchange data were collected 
for two minutes prior to exercise, while the subject was seated on the cycle ergometer or standing 
on the treadmill, as well as throughout exercise.  Heart rate (HR) was measured with a portable 
heart rate monitor (Polar Electro-Oy S610i, Kemple, Finland) and averaged over 5 second 
intervals.  Minute ventilation (VE), rates of oxygen consumption (VO2) and carbon dioxide 
production (VCO2), and the respiratory exchange ratio (RER = VCO2/VO2) were measured breath-
by-breath and averaged over 5 second intervals (MedGraphics CPX/D, St. Paul, MN, USA).  
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Submaximal gas exchange and HR values were calculated by averaging all 5 second samples 
recorded between the 3 min 50 s and 4 min 45 s period of the first five minute exercise stage. To 
identify peak values, HR and gas exchange variables were averaged over 15 second intervals and 
the highest values recorded during the last three minutes of the exercise test were taken as the 
peak values.  
 
The ankle:brachial index (ABI) was measured in triplicate at rest, after 20 minutes of lying 
quietly, in both legs.   The ABI was calculated using the systolic pressures of the highest brachial 
artery and the higher of the dorsalis pedis or posterior tibial arteries, all of which were measured 
within 60 s of each other.  An average resting ABI value for each leg was obtained by averaging 
the closest two of the triplicate measures.  Immediately after each exercise test, subjects returned 
to a supine position and single measures of the ABI of both legs were repeated at 2, 4, 6, 8 and 10 
minutes after exercise.  The same ankle and brachial arteries used to calculate the resting ABI 
were measured during the post-exercise period.  Ankle pressures were measured with an 
inflatable cuff and Doppler ultrasound (8MHz) probe (Huntleigh Muti-Doplex, Cardiff, UK), 
while brachial pressures were measured with an automated pressure monitor (Criticon Dinamap, 
Florida, U.S.A).   
 
Data Analysis  Only values of variables measured during the last of the baseline tests and 
the post-training test were included in the analyses described below. Difference or “change” 
scores were calculated as the difference between the last of the baseline test and post-training test 
scores. All variables were tested for normality using the Kolmogorov-Smirnov test, and in cases 
where variables were not normally distributed a log transformation was applied to stabilise the 
variance. A three-way repeated measures ANOVA (group; time; limb) was used to detect main 
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effects and interactions for the resting and post-exercise (minimum value) ABI data. A two-way 
repeated measures ANOVA was used to detect main effects (group; time) and interactions (group 
× time) for all other variables. The “time” factor represents the six week period of training. 
Tukey’s HD test was used to locate differences when an ANOVA result was significant. 
Relationships between variables were established using Pearson’s correlation coefficient. All data 
are expressed as means and SDs, unless otherwise stated. Statistical significance was set at p < 
0.05. 
 
 
 
 
Results 
Baseline characteristics of the 42 claudicants are shown in Table 1. Patients were well matched 
for age, gender and cardiovascular risk factors. Smoking behaviour and exercise behaviour 
beyond the supervised training were assessed using validated questions from the National Health 
Survey of Australia, and these behaviours remained unchanged in all subjects over the training 
period. The lack of change in exercise behaviour was also confirmed by the results of physical 
activity surveys that were conducted before and after training.  There were no significant main 
effects (group or time) or interaction for resting and post-exercise (treadmill and cycle) ABI 
responses, body weight and resting heart rate, suggesting these responses were similar before and 
after training.  
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Training Sessions Subjects in the treadmill group completed a similar number of training 
sessions (16.6 ± 1.0) as those in the cycle group (17.0 ± 2.3), and the total dose of training was 
not different (p = 0.37) between the treadmill (22.04 ± 7.64 MET hours) and cycle (22.64 ± 7.46 
MET hours) groups. The heart rate at the end of each exercise bout, averaged over all training 
sessions, was not significantly different (p = 0.14; student’s t-test) between the cycle (114 ± 24 
bpm) and treadmill (101 ± 19 bpm) groups.  Mean claudication pain severity during cycle 
training was 1.2 ± 0.7 in the high ABI leg and 1.6 ± 0.5 in the low ABI leg. These values were 
significantly higher (p < 0.05) than the corresponding values observed in the treadmill training 
group (0.5 ± 0.5 and 1.0 ± 0.7 respectively).  
 
Treadmill Test  Prior to training, neither MWT nor PFWT were different between the 
groups. As shown in Figure 1, MWT was significantly increased by training in the treadmill 
group (mean difference = 240 s; 95% CI = 119-361 s); whereas there was no significant change 
in the cycle (mean difference = 48 s; 95% CI = -22 – 117 s) or control group (mean difference = -
10 s; 95 % CI = -90 – 71 s). This change in MWT in the treadmill group was significantly greater 
than the corresponding change scores in the cycle and control groups. This outcome was not 
affected by the exclusion of two claudicants who reported  only mild or moderate claudication 
during the baseline treadmill test. As shown in Figure 2, following training PFWT was 
significantly longer (p < 0.05) for the treadmill group (412 ± 251 s to 607 ± 369 s) compared with 
the cycle group (271 ± 289 s to 263 ± 293 s) and control group  (391 ± 411 s to 446 ± 442 s).  
Submaximal and peak responses for heart rate and pulmonary gas exchange measurements during 
the treadmill test are shown in Tables 2 and 3. In the treadmill group, the change in MWT was 
significantly correlated (p < 0.05) with the training-induced changes in submaximal heart rate (r 
 9
= - 0.55; 95 % CI = -0.73 - -0.30), peak VO2 (l min-1; r = 0.77; 95 % CI = 0.61 – 0.87) and peak 
heart rate (r = 0.54; 95 % CI = 0.28 – 0.72). 
 
Cycle Test  Prior to training, MCT was not significantly different between the groups. 
As shown in Figure 3, MCT was significantly increased by training in the cycle group (mean 
difference = 93 s; 95 % CI = 45 - 132 s); whereas it was not significantly increased in the 
treadmill (mean difference = 45 s; 95 % CI = -60 – 149 s) or control group (mean difference = 51 
s; 95 % CI = -128 – 230 s) (Figure 3). This change in MCT in the cycle group was significantly 
greater than the corresponding change score in the control group; but it was not significantly 
greater than the change score in the treadmill group. PFCT was also not different between the 
groups prior to training, and it was not affected by training (Figure 4). Submaximal and peak 
responses for heart rate and pulmonary gas exchange measurements during the cycle test are 
shown in Tables 2 and 3. In the cycle group, the change in MCT was not correlated with any 
other measured variable. 
 
Cycle versus Walking Tests  For the entire cohort, pain-free times on the baseline cycle 
and treadmill tests were not significantly different from each other; whereas MWT was 
significantly larger than MCT (difference = 179 ± 410 s; 95 % CI = 51.7 to 307.5 s; paired t-test). 
Submaximal and peak physiological responses were not different between these cycle and 
treadmill tests. Many of these responses to both baseline exercise tests (i.e. cycle vs treadmill) 
were significantly correlated (p < 0.05), particularly maximal exercise time (r = 0.75), peak VO2 
(r = 0.91) and ABI two minutes after exercise in the low ABI (r = 0.83) and high ABI leg (r = 
0.86).  The number of symptoms that limited performance and were cited as the reasons for 
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stopping exercise varied between one and three and there was some variation in the anatomical 
location of these symptoms. For the baseline treadmill test these symptoms included pain in the 
calves (n = 33), gluteals (n = 8), hamstrings (n = 7) and quadriceps (n = 4), as well as dyspnoea 
(n = 5) and ‘general fatigue’ (n = 5). Six subjects did not cite claudication as a main reason for 
stopping treadmill exercise, although four of them reported maximal claudication pain during the 
test. Two of these subjects reported only mild or moderate pain during baseline treadmill testing, 
despite the fact that they reported maximal claudication during the screening treadmill test prior 
to baseline testing. For the baseline cycle test the limiting symptoms included pain in the 
quadriceps (n = 27), calves (n = 16), hamstrings (n = 2) and gluteals (n = 1), as well as dyspnoea 
(n = 8) and general fatigue (n = 4).  Five subjects did not cite claudication as a main reason for 
stopping cycle exercise, and two of them did not experience claudication during the test. Half of 
the subjects (n = 21) shared at least one similar limiting symptom between the baseline cycle and 
treadmill tests.   
 
Treadmill training had a significantly larger effect (p < 0.05) on MWT (240 ± 178 s) than cycle 
training had on MCT (93 ± 98 s). Training pain level in the low ABI limb tended to be correlated 
(p = 0.06) with the effect of treadmill training on MWT (r = - 0.54; n = 13; 95 % CI = -0.84 -
0.02); but it was not correlated (r = - 0.2) with the effect of cycle training on MCT. In all trained 
subjects, training pain level in the low ABI limb was inversely correlated to the specific effect of 
training on maximal exercise time (r = -0.53; n = 28; 95 % CI = -0.75 - -0.20). With respect to the 
effects of training on cycle and treadmill performance in all trained subjects (n = 28), there were 
no significant correlations between the changes in maximal cycling and treadmill times (r = 0.01 
- 0.27). However, there was a significant correlation between the training-induced changes in 
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maximal cycle and treadmill times in those subjects who reported at least one limiting symptom 
that was in the same anatomical location during treadmill and cycle exercise before training (Fig. 
5A); but there was no correlation in those who reported limiting symptoms in a different 
anatomical location during treadmill and cycle exercise (Fig. 5B).  Age was also significantly 
correlated with the effect of cycle training on MWT (r = 0.62; p < 0.05). 
 
Responders versus Non-responders  For each subject who trained, a positive response to 
training occurred if the effect of training on maximal exercise time exceeded the difference 
between the last two baseline tests (i.e. MWT for treadmill group; MCT for cycle group). 
According to this criterion, 11 out of the 13 subjects in the treadmill group and 8 out of the 15 
subjects in the cycle group responded positively to training. A similar analysis in the control 
group (i.e. post-pre scores versus baseline variation) revealed three responders for MWT and one 
responder for MCT. Comparisons of baseline characteristics, baseline performances and training 
variables between responders (n = 19) and non-responders (n = 9) were performed. Only training 
pain severity in the low ABI leg was significantly different (p < 0.05) between the responders 
(1.1 ± 0.7) and non-responders (1.8 ± 0.6). 
   
Discussion 
Optimising the exercise program for claudicants depends on knowing the effects of the various 
dimensions of training, such as intensity, duration and mode. A metaanalysis of training studies 
performed up until the mid-1990s suggested that an optimal exercise program aimed at 
improving walking performance should use walking as the mode of exercise 4. This suggestion, 
however, was based on studies that did not systematically compare the effects of alternative 
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modes of exercise with walking. The present study is the first to contrast cycle with treadmill 
training, controlling for all other major dimensions of training, and it is one of only eight 
randomized controlled exercise trials to have studied more than 40 patients. Six weeks of 
treadmill training improved graded walking performance by, on average, 25 %. In contrast, cycle 
training did not improve graded walking performance, despite the finding that it significantly 
improved graded cycle performance. In addition, although treadmill training improved walking 
performance, it failed to increase cycle performance. These preliminary findings suggest that the 
training effects induced by cycling or walking are specific to the mode of exercise used during 
training and that there is no “cross-training” benefit.  
  
In the treatment of walking intolerance, the efficacy of alternative modes of exercise requires that 
there is a significant transfer of physiological adaptation to walking. The findings of our study 
suggest that this is generally not the case for cycling, despite the strong associations between 
cycling and walking performance before and after training (r = 0.72 - 0.75). Claudication in the 
calf and quadriceps muscles were the most frequently cited symptoms during treadmill walking 
and cycling respectively. It is perhaps this difference in the location of claudication between the 
two modes of exercise that has lead some to suggest that cycling would not be beneficial to PAD 
patients who most frequently claudicate in the calf 15. However, the number of limiting symptoms 
during both modes of exercise varied between one and three (see Results), and 50 % of the 
subjects reported a similar limiting symptom during cycling and treadmill exercise. Among the 
two groups of claudicants that trained (n = 28) and who had a similar limiting symptom between 
cycling and walking (n = 12), evidence of a cross-training effect was observed in the form of a 
significant association between the training effects on maximum walking and cycle times (Figure 
5). Seven of these claudicants were in the cycle group, and five of them improved their maximum 
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walking time (mean increase = 35 %) beyond the baseline variation in this measurement and by 
more than the mean response seen in the treadmill group. These data suggest that the similarity of 
symptoms between cycling and walking might help determine the effect of cycle training on 
walking performance. However, age was also positively related to the effect of cycle training on 
maximum walking time, and so we cannot exclude the possibility that age affects the 
responsiveness to training. Further research is clearly required to explore if the similarity of 
symptoms between exercise modes and/or age influences the performance benefit obtained from 
cycle training.  
 
A novel finding of the present study was the larger effect of treadmill training on maximal 
walking time compared with the effect of cycle training on maximal cycle time. This larger, 
specific effect of treadmill training (mean increase = 24 vs 10 %) could not be attributed to 
differences in any of the measured baseline characteristics (Table 1) or other dimensions of 
training, which were similar between the training programs. Excluding nonresponders from 
analyses had little effect on this difference in training effect. In contrast, levels of training pain in 
both limbs were significantly higher in the cycle than the treadmill group, and training pain level 
in the low ABI limb was inversely related to the specific effect of training on maximal exercise 
time.  These data raise the possibility that the smaller training response to cycling might be 
related to the significantly higher pain levels reported by the cycle group. Moreover, they suggest 
that in response to both forms of training a greater improvement in exercise tolerance occurred in 
those subjects who experienced lower and mild levels of claudication pain during the training 
sessions. This conflicts with the suggestion that an optimal training program for claudicants 
consists of exercise to near-maximal pain 4. Further study of this link between training pain and 
 14
physiological adaptation to training is required because the present data suggest that high levels 
of claudication pain might not be optimal. 
 
Although a number of studies have examined the training effects of cycling combined with other 
forms of exercise, only one other study has tested the effects of cycle training alone 6. That study 
reported that walking performance was improved significantly by cycle training. In trying to 
explain how this effect differs from that observed in the present study, several factors need to be 
considered. First, it is unlikely that the training stimulus was relatively lower in the present study 
because the training program was modeled on that used by Walker et al. 6 and training was 
performed more frequently (3 vs 2 sessions per week). Moreover, the increase in cycle 
performance and peak VO2 demonstrates that it provided a significant physiological stimulus. 
Second, our familiarization routine of several baseline testing sessions 9,11-14,16 might help reduce 
the confounding influence that task learning and lowered anxiety makes to the so-called training 
responses, and it is not clear what familiarisation was provided in the other study 6. Third, in 
contrast to the treadmill testing of one patient at a time, these investigators used an indoor shuttle 
walk test where ‘more than one patient’ was tested simultaneously. All but one of the 24 subjects 
in their cycle training group appeared to improve their maximum walking distance, and this 
relatively homogenous response raises the question as to the psychological influence of training 
and performing tests together on an individual’s walking performance after training. Fourth, one 
subject in their study appeared to improve their performance by more than 1000 %, and while this 
wouldn’t affect the significance of the group effect it would greatly inflate the average size of the 
effect reported (i.e. 50 %).  Fifth, the symptoms that limited walking performance were not 
reported in this study, and the heart rates measured during exercise (~160 bpm) far exceed the 
maximal heart rates of 110-120 bpm observed in the present and other studies 2,9,20. This raises 
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the possibility that cardiac dysfunction and symptoms other than claudication contributed more to 
exercise limitations than was the case in the present study.  
 
Over several decades there has been considerable interest in the physiological mechanisms that 
underpin the training effect on exercise tolerance in PAD 3,17,18; yet despite this and the large 
number of factors suggested to be involved in the training response this problem is not well 
understood 19. An improvement in performance might be underpinned by an improvement in 
exercise time in the absence and/or presence of pain, as well as the physiological responses 
associated with these two phases of exercise. In the present study, pain-free time during the 
treadmill test was improved significantly by treadmill training, and this improvement explained 
more than 80 % of the increase in maximal time on this test. In contrast, cycle training had no 
significant effect on pain-free time during the cycle test and, thus, made very little contribution to 
the increase in maximal cycle time. Thus, the specific effect of training differs markedly between 
cycling and walking: the improvement in maximal performance induced by both modes of 
training is linked mainly to a delay in the onset of pain for walking, and an extension of the time 
spent exercising with pain for cycling. This novel finding raises the possibility that the 
physiological adaptations to training also differ between cycling and walking.  
 
In the present study, we used a graded exercise protocol with an initial stage of 5 min duration 
that enables physiological responses to reach a steady-state in most patients 12,13,16. For treadmill 
exercise, there was a tendency towards a significant interactive effect on submaximal VO2 
(group-by-test: p = 0.07), where VO2 was lowered by training in the treadmill, but not cycle, 
group. These data are consistent with the above-mentioned effects of treadmill training on pain-
free time during treadmill walking, demonstrating a link between increased time without pain and 
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a lowered O2 cost of exercise during this mode of exercise.  These findings are similar to those 
observed after the same 6,20 or longer periods of training 2,5,20, where VO2 and blood lactate 
concentration during treadmill exercise were reduced by treadmill training.  However, neither of 
these studies nor the present study shed light on how the oxygen cost of exercise was lowered; 
but it might relate to improved walking technique, recruitment of a smaller number of motor units 
and/or recruitment of less economical type II muscle fibres 11. In contrast to the submaximal VO2 
response, peak VO2 was not significantly increased during treadmill exercise by treadmill 
training, a finding consistent with the only other training study of the same duration to have made 
these measurements 20. However, peak VO2 during cycle exercise was significantly increased by 
cycle training.  This suggests that the improvement in cycle performance in the cycle group, 
which was underpinned by an increase in the time spent exercising with pain, was linked to 
increases in the peak rates of O2 delivery to, and/or O2 consumption by, working muscles. 
 
Some limitations of this study should be considered. Although the sample size of this study 
compares favourably with other randomized controlled exercise training studies, small effects 
might go undetected and a type II error might have occurred. This probably applies most to the 
effect of cycle training given that it increased walking performance by an average of ~5 % more 
than the effect observed in the control group. Whether or not such an effect on a graded test 
translates into a clinically relevant effect in the life of a patient is difficult to determine at present. 
The study was powered to detect larger differences (~10 %) in graded treadmill performance than 
were observed for the control group; but given the natural variation in exercise performance as 
measured in our hands (CV~5-10 %), improvements less than this are of questionable 
significance, from a physiological and clinical perspective. Given the number of comparisons 
made in this study and the fact the we did not adjust the level of significance accordingly, we 
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acknowledge that we might have committed a type I error for any of the significant effects or 
correlations we observed . The duration of the study was restricted to 6 weeks, and given that 
longer training programs will elicit larger increases in performance, it is possible that the present 
study underestimates the training benefit that might be obtained with cycling. However, the 
duration of the training program studied here is consistent with the trend in some countries, such 
as Australia and the U.S., of providing relatively short periods of supervised intervention that are 
then followed by longer periods of home-based intervention and allied health support.  
 
In conclusion, this is the first study to compare the effect on walking performance induced by 
cycle or treadmill training in PAD patients with claudication. On average, cycle training over a 
six week period did not significantly improve walking performance. There was, however, 
considerable variation in the response to cycle training, with five out of the 15 claudicants in the 
cycle group improving their walking performance. This responsiveness to training might be 
influenced by age, the severity of muscle pain during training and/or the similarity of symptoms 
between cycling and walking. These preliminary findings deserve further study before cycle 
training is abandoned as a potential exercise prescription for selected patients with claudication.   
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Figure Captions 
 
Figure 1. Maximum walking times before and after training for patients in the treadmill, cycle 
and control groups. Figure shows individual walking times (—) and mean values (●). * Indicates 
a significant change in MWT from pre-training to post-training in the treadmill group.        
Figure 2. Pain-free walking times before and after training for patients in the treadmill, cycle and 
control groups. Figure shows individual walking times (—) and mean values (●).† a significant 
main effect where the treadmill group was greater than the cycle group. ‡ a significant main 
effect where post-training values were greater than pre-training values.    
Figure 3. Maximum cycling times before and after training for patients in the treadmill, cycle and 
control groups. Figure shows individual walking times (—) and mean values (●).* a significant 
effect of training on MCT in the cycle group.  
 
Figure 4. Pain-free cycling time before and after training for patients in the treadmill, cycle and 
control groups. Figure shows individual walking times (—) and mean values (●).  
Figure 5. The relationship between the training-induced changes in maximal treadmill and cycle 
times in claudicants who reported at least one exercise-limiting symptom that was in the same 
anatomical location (A) or exercise-limiting symptoms that were in a different anatomical 
location (B) during baseline treadmill and cycle tests.  
 
 
 
Table 1. Baseline characteristics of the entire cohort of claudicants and the three experimental groups. 
 
 Entire cohort Treadmill Cycle Control 
Number 42 13 15 14 
Males 24 8 8 8 
Females 18 5 7 6 
Age (y) 63 (9) 62 (6) 65 (10) 61 (10) 
Weight (kg) 74.9 (14.6) 76.5 (17.2) 72.2 (12.7) 76.5 (14.6) 
Heart Rate (bpm) 70 (11) 68 (13) 72 (11) 69 (10) 
Systolic Blood Pressure (mmHg) 
Diastolic Blood Pressure (mmHg) 
139 (16) 
69 (8) 
142 (16) 
69 (8) 
141 (19) 
68 (8) 
134 (13) 
72 (7) 
ABI 
High ABI leg 
Low ABI leg 
 
0.96 (0.26) 
0.69 (0.16) 
 
0.97 (0.25) 
0.67 (0.11) 
 
0.84 (0.27) 
0.64 (0.18) 
 
1.08 (0.20)* 
0.77 (0.14) 
Clinical History 
Stroke 
MI 
Diabetes 
 
9 
8 
12 
 
2 
3 
4 
 
3 
4 
4 
 
4 
1 
4 
Medications 
Antihypertensives 
Lipid lowering 
Anticoagulants & antithrombotics 
Hypoglycaemic agents 
Insulin 
Beta blockers 
Antiangina 
Asthma medication 
 
22 
28 
33 
7 
4 
9 
7 
3 
 
9 
7 
10 
3 
2 
3 
3 
1 
 
7 
10 
12 
3 
2 
3 
3 
0 
 
6 
11 
11 
1 
0 
3 
1 
2 
Smoking 
Current 
Reformed 
 
11 
24 
 
4 
7 
 
1 
11 
 
6 
6 
 
* a significant difference between the control and cycle groups. 
Table 1
Table 2. Submaximal physiological responses during the maximal exercise tests in the three 
experimental groups. Comparisons have only be made between values pertaining to a given exercise 
test. “Pre” refers to the last of the baseline tests, and “post” refers to the test performed at the end of six 
weeks of training. 
 
  
Treadmill Test 
 
 
Cycle Test 
 Pre Post Pre Post 
 
HR 
(bpm) 
Treadmill 
Cycle 
Control 
 
 
 
† 
 
89 (14) 
104 (21) 
93 (12) 
 
 
 
88 (13) 
103 (18) 
92 (11) 
 
 
 
93 (15) 
106 (23) 
93 (13) 
 
 
 
95 (14) 
104 (27)* 
94 (17) 
VO2 
(ml min-1) 
Treadmill 
Cycle 
Control 
 
 
‡ 
 
726 (185) 
741 (205) 
695 (190) 
 
 
689 (234) 
752 (211) 
669 (157) 
 
 
693 (134) 
692 (90) 
674 (77) 
 
 
687 (163) 
673 (100) 
666 (72) 
VO2 
(ml kg-1min-1) 
Treadmill 
Cycle 
Control 
 
 
 
 
9.6 (1.6) 
10.1 (1.5) 
9.0 (1.2) 
 
 
9.0 (1.6) 
10.3 (1.7) 
8.7 (1.1) 
 
 
9.2 (1.3) 
9.5 (1.0) 
9.0 (1.4) 
 
 
9.1 (1.4) 
9.4 (1.1) 
8.9 (1.1) 
RER 
Treadmill 
Cycle 
Control 
 
 
 
0.96 (0.09) 
0.98 (0.06) 
0.95 (0.09) 
 
0.96 (0.08)
0.97 (0.07)
0.96 (0.08)
 
1.07 (0.09) 
1.12 (0.13) 
1.05 (0.11)
 
1.08 (0.09) 
1.08 (0.11) 
1.07 (0.10)
VE 
(l min-1) 
Treadmill 
Cycle 
Control 
 
 
 
23.6 (6.7) 
24.2 (6.3) 
22.5 (7.5) 
 
 
22.2 (7.2) 
24.4 (5.7) 
22.0 (6.3) 
 
 
24.5 (4.9) 
24.9 (3.0) 
22.7 (3.0) 
 
 
24.3 (5.9) 
24.1 (3.7) 
23.5 (2.5) 
 
* a significant effect of training in the cycle group. † a main effect where the cycle group is greater 
than the treadmill group. ‡ a main effect where the cycle group is greater than the control group. 
Table 2
Table 3. Peak physiological responses during the maximal exercise tests in the three experimental 
groups. Comparisons have only be made between values pertaining to a given exercise test. “Pre” 
refers to the last of the baseline tests, and “post” refers to the test performed at the end of six weeks of 
training. 
 
  
Treadmill Test 
 
 
Cycle Test 
 Pre Post Pre Post 
 
HR 
(bpm) 
Treadmill 
Cycle 
Control 
 
 
 
 
 
115 (23) 
122 (19) 
127 (27) 
 
 
 
118 (20) 
123 (19) 
127 (24) 
 
 
 
123 (25) 
131 (25) 
128 (26) 
 
 
 
125 (24) 
131 (26) 
127 (24) 
VO2 
(ml min-1) 
Treadmill 
Cycle 
Control 
 
 
 
† 
 
1140 (307) 
1052 (384) 
1263 (418) 
 
 
1202 (308)
1154 (406)
1251 (435)
† 
 
1126 (291) 
1041 (370) 
1236 (446)
 
 
1166 (337) 
1115 (395) 
1221 (423)
VO2 
(ml kg-1min-1) 
Treadmill 
Cycle 
Control 
 
 
 
† 
 
15.2 (4.0) 
14.4 (4.4) 
16.6 (4.9) 
 
 
15.8 (2.3) 
15.8 (4.8) 
16.4 (4.9) 
 
 
15.0 (3.7) 
14.4 (4.6) 
16.2 (4.9) 
 
 
15.6 (4.0) 
15.4 (4.9)* 
16.1 (4.7) 
RER 
Treadmill 
Cycle 
Control 
 
 
 
1.15 (0.09) 
1.17 (0.10) 
1.22 (0.07) 
 
1.19 (0.09)
1.18 (0.10)
1.20 (0.11)
† 
1.29 (0.10) 
1.34 (0.11) 
1.32 (0.09)
 
1.29 (0.11) 
1.30 (0.11) 
1.28 (0.11)
VE 
(l min-1) 
Treadmill 
Cycle 
Control 
 
† 
 
41.7 (12.2) 
40.5 (12.9) 
49.1 (18.6) 
 
 
44.8 (9.8) 
 44.1(12.3)
49.1 (21.6)
 
 
49.2 (11.9) 
46.7 (10.7) 
56.0 (25.8)
 
 
49.2 (12.4) 
48.9 (10.6) 
53.0 (22.5)
* a significant effect of training in the cycle group for the treadmill and cycle test.   
† a main effect where post-training values are significantly different from pre-training values for the 
test (treadmill and/or cycle) indicated. 
Table 3
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